Apellis Pharmaceuticals Inc
NASDAQ:APLS

Watchlist Manager
Apellis Pharmaceuticals Inc Logo
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Watchlist
Price: 24.175 USD -1.57%
Market Cap: 3.1B USD

Apellis Pharmaceuticals Inc
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Apellis Pharmaceuticals Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$10.7B
CAGR 3-Years
-72%
CAGR 5-Years
-60%
CAGR 10-Years
-27%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$843m
CAGR 3-Years
38%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
-$3.2B
CAGR 3-Years
-87%
CAGR 5-Years
N/A
CAGR 10-Years
-35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$543m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
-60%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$245.5m
CAGR 3-Years
26%
CAGR 5-Years
-10%
CAGR 10-Years
-20%
No Stocks Found

Apellis Pharmaceuticals Inc
Glance View

In the realm of biotechnology, Apellis Pharmaceuticals Inc. has carved out a niche by pioneering therapies that target the complement system, an integral part of the immune response. Founded in 2009, the company quickly honed in on the inhibition of C3, a protein central to the activation of the complement cascade, which can drive various diseases when dysregulated. Through its proprietary platform, Apellis has developed novel therapeutic candidates that aim to modulate the immune system from an entirely fresh angle. The company focuses on addressing serious medical conditions that currently have limited treatment options, such as age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH), by employing targeted therapies to reduce inflammation and improve patient outcomes. Apellis’s business strategy revolves around a model that not only aims to bring innovative treatments to market but also to establish partnerships that broaden the reach of its technology. The company's flagship drug, Empaveli, received FDA approval for PNH in 2021 and underscores its potential to capture larger market segments within rare disease treatment areas. By investing heavily in research and development, Apellis seeks to expand its pipeline while also collaborating with other firms to enhance its capabilities and share the risks and rewards associated with drug development. Revenue is generated primarily through sales of its approved therapies, as well as milestone payments and royalties from partnerships, setting Apellis on a path poised for growth if it continues to advance its clinical programs successfully.

APLS Intrinsic Value
HIDDEN
Show

See Also

Back to Top